---
title: "Descartes-08 in Generalized myasthenia gravis: Care management intervention strategies"
description: "Formulary evidence on Descartes-08 in Generalized myasthenia gravis: Care management intervention strategies. Topics: Treatment goal of minimal manifestation status: international consensus guidance, Minimal symptom expression as a patient-reported treatment goal, Steroid-sparing strategy and tapering, Monitoring for adverse effects of immunosuppression, and 17 further topics. 21 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description/care-management-intervention-strategies"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Descartes-08 in Generalized myasthenia gravis: Care management intervention strategies

<a id="heading-2.2.2.4"></a>

## 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

### Treatment goal of minimal manifestation status: international consensus guidance

> “Goals for the treatment of MG. MGFA Task Force Post-Intervention Status (PIS) classification Minimal Manifestation Status (MMS) or better,3 with no more than grade 1 Common Terminology Criteria for Adverse Events (CTCAE) medication side effects.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

<a id="topic-2.2.2.4-2"></a>

### Minimal symptom expression as a patient-reported treatment goal

> “‘Minimal symptom expression’ was defined as MG-ADL total score of 0–1 or MG-QOL15 total score of 0–3.”

Source: [Vissing et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7320935/)

> “MSE using the MG‐ADL shows promise in helping to determine success of treatment and may be the aspirational goal of MG treatment for the future once validated, particularly given the evolving treatment landscape in MG.”

Source: [Muppidi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9302997/)

> “MSE, as a patient‐centric endpoint, can be used alongside clinician‐assessed measures and safety measures to support an integrated treatment goal that encompasses both efficacy and tolerability for the treatment of gMG.”

Source: [Meisel et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13093530/)

<a id="topic-2.2.2.4-3"></a>

### Steroid-sparing strategy and tapering

> “Tapering of IS drugs is associated with risk of relapse, which may necessitate upward adjustments in dose. The risk of relapse is higher in patients who are symptomatic, or after rapid taper. d. It is usually necessary to maintain some immunosuppression for many years, sometimes for life.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

> “Patients with generalized MG should be given a non‐steroid immunosuppressant to achieve a better clinical response and enable steroid dose reduction.”
> “Tapering of corticosteroids, and non‐steroidal immunosuppressants, should be considered after 1–2 years in patients in stable remission or with minimal symptoms.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.4-4"></a>

### Monitoring for adverse effects of immunosuppression

> “Patients must be monitored for potential adverse effects and complications from IS drugs. Changing to an alternative IS agent should be considered if adverse effects and complications are medically significant or create undue hardship for the patient.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

> “All patients on steroids should be monitored for blood pressure, body weight, bone mineral density, blood glucose levels, sleep, and mood problems.”
> “Due to spontaneous disease fluctuations, comorbidities, and changes in life conditions, regular long‐term specialized follow‐up is needed.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.4-5"></a>

### Monitoring disease activity with MG-ADL and QMG

> “The QMG takes up to 25 min to complete and requires technician training, a hand‐held dynamometer, a spirometer, and a stopwatch.”
> “The MG‐ADL is easy to administer, requires no additional training, is quick to complete (<10 min), and can be used in routine clinical practice or in clinical trials.”
> “A 2‐point change seemed to provide the best balance between sensitivity (77%) and specificity (82%); thus, this analysis revealed that a 2‐point improvement in MG‐ADL score best indicated clinical improvement.”

Source: [Muppidi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9302997/)

<a id="topic-2.2.2.4-6"></a>

### Physical training and shared goal setting: Nordic guidance

> “Adapted physical training is recommended.”
> “Patients and doctors should together define ambitious treatment goals”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.4-7"></a>

### Monitoring for CRS, ICANS, and hematotoxicity after CAR T-cell therapy in autoimmune disease: EBMT recommendations

| Topic | EBMT recommendation for autoimmune disease |
| --- | --- |
| CRS, ICANS, and ICAHT | “As hematological patients. The early and prompt treatment of these complications is highly recommended in AD setting.” |
| Blood counts | “As for hematological patients; monitoring of blood counts is mandatory in ADs (e.g. at every visit and as clinically indicated, including long-term follow up to evaluate risk of ICAHT).” |
| Prophylactic G-CSF | “Administration of G-CSF may induce disease flare in ADs. Prophylactic use of G-CSF is not recommended.” |

Source: [Greco et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10867419/)

<a id="topic-2.2.2.4-8"></a>

### Hospitalization, distance to the treating center, and caregiver presence after CAR T-cell therapy: EBMT recommendations

> “For hospitalization and distance to the accredited treating center, we refer to current EBMT guidelines for CT and ideally up to 14 days for AD patients without severe reactions. Patients should be located within 60 min of the center with the continuous presence of a caregiver educated to identify the potential complications maintained for a year.”

Source: [Greco et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10867419/)

<a id="topic-2.2.2.4-9"></a>

### Daily CRS and ICANS monitoring and myelotoxicity surveillance: CD19 CAR T-cell case series in MG

> “Patients were monitored daily for the development of CRS and immune effector cell–associated neurotoxicity syndrome (ICANS) during the first 10 days following anti-CD19 CAR T cell infusion.”
> “Myelotoxicity was defined as grade III or IV neutropenia or leukocytopenia persisting for more than 28 days and was monitored prospectively using regular laboratory assessments, performed several times per week during the first 30 days, approximately biweekly between days 30 and 90, and at longer intervals thereafter.”
> “Long-term observation revealed an episode of pneumonia in patient MG3, associated with B cell aplasia and hypogammaglobulinemia.”

Source: [Hegelmaier et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13589498/)

<a id="topic-2.2.2.4-10"></a>

### Neutropenia, infection, and hypogammaglobulinemia management after lymphodepletion and CAR T-cell infusion: phase 1 trial in refractory gMG

> “For neutrophil deficiency (absolute neutrophil count less than 1.0 × 109/L), granulocyte colony-stimulating factor and prophylactic antibiotics (mostly sulfamethoxazole and cephalosporins) were given.”
> “For those with severe infections or hypogammaglobulinemia (IgG less than 4 g/L), 0.4–0.6 g/kg of intravenous immunoglobulin was administered.”

Source: [Zhang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12615342/)

<a id="topic-2.2.2.4-11"></a>

### Antimicrobial prophylaxis after CAR T-cell therapy: EBMT recommendations

> “The risk of infection depends on the AD and degree of immunosuppression, and management should be carefully discussed upfront by a multidisciplinary team meeting (disease specialist, infection-disease specialist, hematologists and CART experts). A follow-up of potential infectious complications should be considered mandatory.”
> “Sufficiently long anti-viral and antibacterial prophylaxis should be maintained according to patient individual risk and in line with institutional guidelines and current EBMT guidelines.”

Source: [Greco et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10867419/)

<a id="topic-2.2.2.4-12"></a>

### Vaccination before and after CAR T-cell therapy: EBMT recommendations

> “Vaccinations status should be assessed and updated before LD.”
> “Vaccination after CART therapy is effective and risk consideration should guide the decision to vaccinate before the procedure.”
> “Live vaccines are contraindicated in AD patients.”

Source: [Greco et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10867419/)

<a id="topic-2.2.2.4-13"></a>

### Vaccination before immunosuppressive therapy and before complement inhibitors: 2026 international consensus

> “Clinicians should refer patients with MG to their primary care clinician or appropriate specialty (e.g., infectious disease) to complete immunization schedules, per local/national/World Health Organization guidelines and per local prescribing information for MG therapies as part of immunosuppressive therapy planning.”
> “Clinicians should refer patients with gMG for whom complement inhibitor therapies may be a future consideration to their primary care clinician or appropriate specialist to complete meningococcal vaccination and other treatment-specific vaccination, per local/national/World Health Organization guidelines and per local drug prescribing information.”

Source: [Narayanaswami et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13352217/)

<a id="topic-2.2.2.4-14"></a>

### Leukapheresis: T-cell counts, venous access, and immunosuppressant washout: EBMT recommendations

> “To achieve a good product, drug-specific washout periods before leukapheresis have to be considered to optimize T cell fitness as listed in Table 5. Usual recommendations for a successful CART production advice for 200/mcl CD3+ T cell counts, but CD3+ T cell counts >50/mcl can be sufficient. Secure venous access has to be guaranteed in ADs, when planning leukapheresis and lymphodepleting conditioning (LD).”

Source: [Greco et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10867419/)

<a id="topic-2.2.2.4-15"></a>

### Washout of MG-relevant immunotherapies before leukapheresis: EBMT recommendations

| Therapy | Recommendation in autoimmune disease |
| --- | --- |
| Steroids | “May be administered at dosages ≤10 mg/day prednisone (or equivalent), by 7 days before leukapheresis and before LD;” |
| Mycophenolate mofetil, azathioprine, calcineurin inhibitors, mTOR inhibitors, and JAK inhibitors | “Discontinued at least 2 weeks before leukapheresis” |
| Cyclophosphamide and methotrexate | “Discontinued at least 3 weeks before leukapheresis” |
| Belimumab and B cell targeting antibodies (e.g. anti CD20) | “Discontinued at least 1 week before leukapheresis” |

Source: [Greco et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10867419/)

<a id="topic-2.2.2.4-16"></a>

### Timing of immunosuppressants around apheresis and lymphodepletion, and pre-lymphodepletion assessment of pulmonary reserve and bulbar function in MG

> “EULAR–EBMT guidance allows low‐dose prednisone up to 7.5 mg 1 day prior to apheresis but advises tapering cell‐cycle blockers 4 weeks before lymphodepletion so that transduced T‐cells expand without pharmacologic brakes”
> “Trial registries for autoimmune cellular therapies therefore recommend a meticulous pre‐diagnostic evaluation that captures comorbid infection, pulmonary reserve and bulbar function before lymphodepletion is even considered”
> “Application of the Immune Effector Cell‐Associated Encephalopathy (ICE) score beside continuous EEG was able to detect subclinical seizures in almost half of the patients whose formal ICANS grade had remained 0–1, suggesting that conventional grading alone is insufficient once neuromuscular weakness complicates the examination”

Source: [Hegelmaier et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13138368/)

<a id="topic-2.2.2.4-17"></a>

### Prolonged B-cell aplasia, hypogammaglobulinemia, and infections after CAR T-cell therapy

> “A frequent long‐term consequence of anti‐CD19 CAR T‐cell therapy is prolonged B cell aplasia, persisting for years in up to 38% of patients and often resulting in hypogammaglobulinemia and increased infection risk requiring immunoglobulin replacement”

Source: [Hegelmaier et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13138368/)

> “Severe infections are frequent in the early period following CAR-T reinfusion, warranting antimicrobial prophylaxis.”
> “Hypogammaglobulinaemia is typically prolonged and may necessitate treatment of supplemental Immunoglobulin Replacement Therapy.”

Source: [Bradhurst et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13630046/)

<a id="topic-2.2.2.4-18"></a>

### Frequency of CRS, ICANS, hypogammaglobulinemia, cytopenias, and infection after CAR-based therapy in autoimmune disease: meta-analysis of 56 studies

> “Of 3367 records screened, 56 studies met the inclusion criteria (15 eligible for meta-analysis; 41 synthesized qualitatively).”
> “Across all AIDs, CRS of any grade occurred in 0·63, but grade ≥ 3 CRS and any grade of ICANS were negligible (both 0·00). Hypogammaglobulinaemia of any grade occurred in 0·47, while grade ≥ 3 events were rare. Cytopenias were common: neutropenia and anemia of any grade were most frequent. Severe cytopenias occurred in ≤0·3. Infection within 3 months occurred in 0·29.”

Source: [Wong et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42167622/)

<a id="topic-2.2.2.4-19"></a>

### Regular assessment of symptom burden, treatment burden, and quality of life; shared decision making: 2026 international consensus

> “Clinicians should regularly assess a patient with MG at all disease stages for symptom burden, treatment burden, and quality of life, using the same measures to build an ongoing, overall picture of the disease and its impact.”
> “Clinicians should engage patients with MG and their family/caregivers, as appropriate, to play an active role in shared decision making, so that patients' personal goals, values, and preferences are considered when discussing treatment plans.”
> “In patients receiving glucocorticoids, clinicians should aim to reduce the glucocorticoid dose to prednisone equivalent ≤10 mg/d and optimally to ≤5 mg/d, using alternative agents as necessary, and monitor patients closely for MG worsening.”

Source: [Narayanaswami et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13352217/)

<a id="topic-2.2.2.4-20"></a>

### IgG monitoring under FcRn inhibitors and rituximab: German-Austrian expert guidance

> “Drug‐specific safety parameters must be assessed before initiation and at every switch of immunotherapy. These include monitoring of IgG levels under FcRn‐I and RTX therapy (especially when used in combination).”

Source: [Meisel et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13559022/)

<a id="topic-2.2.2.4-21"></a>

### Living consensus recommendations on CAR T-cell therapy for autoimmune diseases: 2026 EBMT, ISCT, and JACIE update

> “In 2024, an international expert panel from the European Society for Blood and Marrow Transplantation (EBMT), the International Society for Cell and Gene Therapy (ISCT), and the Joint Accreditation Committee of ISCT and EBMT (JACIE) released the first best-practice recommendations on CAR T cells for autoimmune diseases.”
> “The 2026 consensus reviews current evidence and expert practices on CAR T cells for rheumatic, neurological, haematological, other autoimmune diseases, and paediatric indications, providing updated, expert-based recommendations on patient selection, diagnostic investigation, clinical management, follow up, and immune monitoring for each disease group.”

Source: [Greco et al. (2026)](https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913%2826%2900249-3/fulltext)

## Related pages
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis.md)
- [Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary.md)
- [Descartes-08 in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Descartes-08 in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence.md)
- [Descartes-08 in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics.md)
- [Descartes-08 in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references.md)
